

- **Name:** Stephen Clarke
  - **Current Position & Affiliation:** Professor of Medicine, University of Sydney  
Chief Medical Officer, Medical Oncology,  
Genesis Care
  - **Country:** Australia
- 

**• Educational Background:**

MBBS- University of Sydney 1983

PhD – University of London 1994

MD – University of Sydney 2011

**• Professional Experience:**

Trained in Medical Oncology in Sydney – FRACP 1990

Clinical Fellow and PhD student in Royal Marsden Hospital, London 1991-94

Staff Specialist in Medical Oncology in Sydney from 1994

**• Professional Organizations:**

ASCO, ESMO, COSA, MOGA

**• Main Scientific Publications in Thoracic Malignancy:**

Hayes SA, Haeftliger S, Harris B, Pavlakis N, Clarke SJ, Molloy MP, Howell VM.

Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. *J Breath Res.* 5;10(3):034001, 2016.

Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. *Lung Cancer.* 102:21-27, 2016 (IF 3.77).

Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke SJ, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MRJ, O’Toole SA, Cooper WA. Screening for *ROS1* gene rearrangements in non-small cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. *Histopathology* 70(3):402-411, 2017 (IF 3.45).

Dhillon HM, Bell ML, van der Ploeg HP, Turner J, Kabourakis M, Spencer L, Lewis C, Hui R, Blinman P, Clarke S, Boyer M and Vardy J. The impact of physical activity on fatigue and quality of life in advanced lung cancer patients: a randomised controlled trial. *Ann Oncol* 28(8):1889-1897, 2017. (IF 7.04).

Itchins M, Chia PL, Hayes SA, Howell VM, Gill AJ, Cooper WA, John T, Mitchell P, Millward M, Clarke SJ, Solomon B, Pavlakis N. Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of

treatment resistance in the Australian context. *Asia Pac J Clin Oncol.* 13 Suppl 3:3-13, 2017.

Itchins M, Clarke S, Pavlakis N. Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics. *Transl Lung Cancer Res.* 7(Suppl 1):S39-S45, 2018.

Itchins M, Hayes SA, Gill AJ, Cooper W, O'Connell R, Howell VM, Clarke SJ, Pavlakis N. Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. *Asia Pac J Clin Oncol* 2018 Apr 19. doi: 10.1111/ajco.12877.

Li BT, Shen R, Buoncore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Ado-trastuzumab emtansine for patients with HER2 mutant lung cancers: Results from a phase II basket trial. *J Clin Oncol* 20;36(24):2532-2537, 2018.

Sabari JK, Stephens D, Offin MD, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Yu H, Paik PK, Chaft JE, Kris MG, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Garg K, Di Pasquo D, Raymond CK, Lim LP, Mi M, Hellman MD, Drilon A, Riely GJ, Rusch V, Jones DR, Rimmer A, Rudin CM, Isbell JM, Li BT. A prospective study of plasma circulating tumor DNA next generation sequencing to guide matched targeted therapy for lung cancers. *J Natl Cancer Inst* 111(6), 575-583, 2018.

Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. *Eur J Cancer.* 109:28-35, 2019.

Alexander M, Pavlakis N, John T, O'Connell R, Kao S, Hughes BGM, Lee A, Hayes SA, Howell VM, Clarke SJ, Millward M, Burbury K, Solomon B, Itchins M. Brief report on thromboembolism in ROS1-rearranged non-small cell lung cancer. *J Thor Oncol* 142:34-40, 2020.

Harris BDW, Phan V, Perera V, Szyc A, Galettis P, Martin JH, Walpole E, McLachlan AJ, Clarke SJ, Reuter SE, Charles KA. Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. *Clin Pharmacokinet.* 2020 Feb 7